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ing taken by 25.7% of patients with an indication; 47.3% of patients with MI or
coronary revascularization were taking a statin compared with 40.4%, 33.8% and
18.9% with diabetes, LDL-C ≥190mg/dL and 10-year CVD risk ≥7.5% respec-
tively (Table 1). In multivariable analysis and compared with patients with history
of MI or coronary revascularization, those with diabetes, LDL-C ≥190 mg/dL, and
10-year CVD risk ≥7.5% were less likely to be taking a statin (prevalence ra-
tio [95% conﬁdence interval] 0.68 [0.58–0.79], 0.71 [0.50–1.01], and 0.39 [0.34–
0.46], respectively). Among patients who had ever taken a statin, 27.7% had dis-
continued treatment before 2013: 23.6% with history of MI or coronary revascular-
ization, 27.7% with diabetes, 30.9% with LDL-C ≥190 mg/dL and 27.9% of those
with 10-year CVD risk ≥7.5%.
Statin use by CVD risk group
CVD risk group Percentage of Percentage taking PR for statin use
population statins (95% CI)
MI or coronary revascularization 2.4% 47.3% 1 (ref)
Diabetes 6.1% 40.4% 0.68 (0.58–0.79)
LDL-C ≥190 mg/dL 0.8% 33.8% 0.71 (0.50–1.01)
CVD risk ≥7.5% 21.9% 18.9% 0.39 (0.34–0.46)
PRs adjusted for age, sex, race, body mass index, glomerular ﬁltration rate, protease inhibitors
or cobicistat, CD4, plasma HIV-1 RNA, other lipid lowering therapy, and site.
Conclusions: A majority of HIV-infected patients with an indication for a statin
were not taking this medication, partially resulting from a high rate of treatment
discontinuation.
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Background: PCSK9 inhibitors have emerged as a promising treatment option
for management of dyslipidemia. The European Society of Cardiology/European
Atherosclerosis Society (ESC/EAS) and the American College of Cardiology
(ACC) have issued recommendations regarding the use of PCSK9 inhibitors in
selected patients. Treatment eligibility rates according to these recommendations
in real-world clinical practice remain unknown.
Purpose: To assess in a contemporary, real-world setting the eligibility for PCSK9
inhibitors after acute coronary syndromes (ACS) according to ESC/EAS vs. ACC
recommendations.
Methods: We analysed a prospective Swiss cohort of 2,023 patients hospitalized
for ACS between 2009 and 2014. Patients received optimal secondary prevention
treatment. One year after enrollment, eligibility for PCSK9 inhibitor treatment was
deﬁned according to the ESC/EAS vs. ACC criteria on the basis of on-treatment
levels of low-density lipoprotein cholesterol (LDL-C); achieved reduction in LDL-
C; and high-risk clinical characteristics (rapid disease progression or comorbidi-
ties). Familial hypercholesterolemia (FH) was deﬁned using the Dutch Lipid Clinic
Network criteria. Because treatment with ezetimibe on top of maximally tolerated
statin is included in both the ESC/EAS and ACC eligibility algorithms, we mod-
elled a ﬁxed relative reduction of 24% in LDL-C levels at one year in all patients
not treated with ezetimibe.
Results: At one year, 94.3% of patients were treated with statin (55.3% with high-
intensity statin) and 5.8% with ezetimibe. Mean LDL-C levels were 2.19±0.86
mmol/l at one year, and 35.8% of patients had LDL-C levels <1.8 mmol/l. Af-
ter simulating the LDL-C-lowering effect of ezetimibe, the proportion of patients
who would be eligible for PCSK9 inhibitor treatment at one year was 2.7% ac-
cording to ESC/EAS criteria vs. 13.4% based on ACC criteria. Respective rates
without modelling the ezetimibe effect would be 10.6% vs. 31.4%. In multivariable
analysis, predictors of treatment eligibility with PCSK9 inhibitors included proba-
ble/deﬁnite FH (OR 3.38, 95% CI 1.70–6.72 for ESC/EAC criteria and 3.99, 95%
CI 2.82–5.64 for ACC criteria; p<0.001) and non-attendance to a cardiac rehabili-
tation program after hospital discharge (OR 0.31, 95% CI 0.16–0.60 for ESC/EAS
criteria and OR 0.48, 95% CI 0.34–0.66 for ACC criteria; p<0.001).
Conclusions: In this sizable cohort of ACS patients receiving contemporary
secondary-prevention treatment for one year, recommendations made by the
ACC would lead to ﬁve times higher eligibility rates for PCSK9 inhibitor treatment
compared with the ESC/EAS statement. EligibilIty rates would increase substan-
tially without the incremental LDL-C-lowering effect by ezetimibe. Coupled with
ﬁndings of large outcomes trials, these observations may have implications for
guiding clinical decision-making and enhancing cost-effectiveness analyses with
regard to rational use of PCSK9 inhibitors.
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Introduction: The plant-derived omega-3 fatty acid alpha-linolenic acid (ALA)
has been associated with potential anti-atherosclerotic properties and has been
suggested as a major explanation behind the beneﬁcial effect of the Mediter-
ranean diet in the prevention of coronary heart disease. However, limited evidence
exists whether ALA is associated with a lower risk of ischemic stroke.
Purpose: The objective was to investigate the association between adipose tis-
sue content of ALA as an objective long-term biomarker of intake of ALA and the
risk of ischemic stroke.
Methods: A total of 57,053 participants aged 50–64 years of age were enrolled
between 1993–97 into the Danish Diet, Cancer and Health Cohort. Potential
cases were identiﬁed through the nationwide Danish National Patient Register
and subsequently validated. Baseline adipose tissue content of ALA was deter-
mined with the use of gas chromatography in all incident cases and in a random
sex-stratiﬁed sample of the total cohort (n=3500). Statistical analyses were per-
formed using sex-stratiﬁed weighed Cox proportional hazard regression adjusted
for established ischemic stroke risk factors. ALA was included as a continuous
and a categorical variable, respectively.
Results: During a median of 13.5 years of follow up, we identiﬁed 1894 cases of
ischemic stroke. After appropriate exclusions, we included 1735 cases for analy-
sis. Multivariate analyses that were conducted using restricted cubic splines and
adjustment for established ischemic stroke risk factors showed a U-shaped as-
sociation between adipose tissue content of ALA and the risk of ischemic stroke,
but this association was not statistically signiﬁcant (Figure). In analyses of adi-
pose tissue content of ALA expressed in quintiles, the hazard ratios in the second
(0.95; 95% CI: 0.78, 1.16), third (0.86; 95% CI: 0.70, 1.06), fourth (0.93 95% CI:
0.76, 1.14) and ﬁfth quintile (1.01 95% CI: 0.82, 1.23) also revealed a U-shaped
association, but the hazard ratios were not statistically signiﬁcant.
Conclusion: We observed a U-shaped association between adipose tissue con-
tent of ALA and the risk of ischemic stroke, but the association was not statistically
signiﬁcant.
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Background: Low density lipoprotein cholesterol (LDL-C) lowering with high
dose statin therapy is a cornerstone in secondary prevention post-myocardial in-
farction (MI) with a treatment goal of <1.8 mmol/L. LDL-C is an established risk
factor for atherosclerotic cardiovascular disease (ASCVD) in the general popu-
lation, but the signiﬁcance of LDL-C for ASCVD risk in post-MI patients remains
unclear and the current LDL-C goal for treatment is based on circumstantial evi-
dence.
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